Mounjaro Cost in Maine 2026: Pricing, Insurance, and Savings Options

What Mounjaro Costs at Maine Pharmacies in 2026

The wholesale acquisition cost (WAC) set by Eli Lilly for Mounjaro is $1,023 per month for a four-pen carton at any dose strength, and Maine retail pharmacies mirror that figure for cash-pay customers. This price applies uniformly whether you fill at a chain pharmacy in Portland, a regional independent in Bangor, or a grocery-store pharmacy in Lewiston. The WAC does not vary by dose. A patient titrating from 2.5 mg to 15 mg pays the same list price at each step.

For context, tirzepatide is a dual GIP/GLP-1 receptor agonist that produced a mean A1C reduction of 2.37% at the 15 mg dose versus 0.51% for semaglutide 1 mg in the SURPASS-2 trial (N=1,879). That head-to-head efficacy profile drives much of the demand in Maine and nationally. Patients without any form of coverage or discount assistance face an annual spend exceeding $12,000. That figure makes understanding every available cost-reduction pathway essential before filling a first prescription.

Maine sits in a region where pharmacy benefit manager (PBM) formulary decisions heavily influence out-of-pocket costs. The three largest PBMs (CVS Caremark, Express Scripts, OptumRx) each maintain separate tirzepatide formulary positions that change at least annually. Checking your specific plan's formulary status before assuming a price is the single most important step a Maine patient can take.

Maine Medicaid Coverage for Mounjaro

Maine Medicaid (MaineCare) covers Mounjaro with prior authorization (PA) for members with a documented diagnosis of type 2 diabetes. The PA process typically requires the prescriber to confirm an A1C at or above a threshold specified in the MaineCare preferred drug list (often 7.0% or higher) and to document that the patient has tried or cannot tolerate metformin, per ADA Standards of Care guidelines. Once approved, the PA is generally valid for 12 months before renewal.

Off-label weight-loss coverage through MaineCare is not currently available for Mounjaro. Eli Lilly markets tirzepatide for obesity under the separate brand name Zepbound, and MaineCare's formulary does not list Zepbound for weight management as of mid-2026. Patients seeking tirzepatide specifically for weight loss through Maine Medicaid will likely receive a denial.

The PA turnaround time varies. Most MaineCare PAs are adjudicated within 24 to 72 hours when submitted electronically through the CoverMyMeds portal. Paper fax submissions can take up to five business days. If denied, prescribers can file a formal appeal, and patients retain the right to request a fair hearing through the Maine Department of Health and Human Services.

Practical tip: ask your prescriber's office to submit the PA before sending the prescription to the pharmacy. A PA submitted simultaneously with or after the pharmacy claim often triggers a point-of-sale rejection that delays pickup by days.

Commercial Insurance Coverage in Maine

Most commercial plans in Maine include tirzepatide on formulary for type 2 diabetes, but tier placement and cost-sharing vary widely. Anthem BlueCross BlueShield, Aetna, Cigna, and Harvard Pilgrim all operate in the Maine market, and each negotiates PBM contracts independently.

Typical tier placement falls into one of three buckets. Preferred specialty tier means a copay between $50 and $150 per fill. Non-preferred specialty tier pushes copays to $150 to $350 per fill. Plans using coinsurance instead of flat copays may charge 25% to 40% of the negotiated price, meaning out-of-pocket costs between $200 and $400 monthly until the out-of-pocket maximum is reached.

Step therapy requirements are common. Many Maine commercial plans require documentation that the patient tried a GLP-1 mono-agonist (typically semaglutide or liraglutide) before approving tirzepatide. The SURPASS-2 trial demonstrated tirzepatide's superiority over semaglutide 1 mg for A1C reduction (2.37% vs. 1.86% at the 15 mg dose), and prescribers can cite this data in appeals when step therapy denials occur.

For employer-sponsored plans governed by ERISA (the majority of large-employer plans in Maine), the state insurance commissioner cannot mandate coverage. Self-funded employer plans set their own formulary rules. If your employer uses a self-funded plan, the HR benefits team or plan document is the authoritative source, not the state insurance department.

The Eli Lilly Savings Card in Maine

Eli Lilly's Mounjaro Savings Card is accepted at Maine pharmacies and can reduce the copay to as low as $25 per 30-day fill for commercially insured patients. The card covers up to $573 per fill, with a maximum annual benefit that Lilly adjusts periodically. Patients with government insurance (Medicare Part D, Medicaid, Tricare, VA) are not eligible for the savings card per federal anti-kickback statute requirements.

Activation is straightforward. Patients register at the manufacturer's website, receive a BIN/PCN/Group number, and present it alongside their commercial insurance card at the pharmacy. The discount applies after the insurer's adjudication, reducing only the patient's copay or coinsurance portion.

There are a few caveats Maine patients should know. The card does not work if the commercial plan excludes Mounjaro entirely. It also will not apply if the pharmacy claim rejects at the PBM level before reaching the adjudication stage. And the annual cap means patients on higher doses who fill 13 times per year (due to timing) may exhaust the benefit before December.

A 2024 IQVIA analysis estimated that manufacturer copay cards reduced average patient out-of-pocket spending on GLP-1 receptor agonists by approximately 60% across commercially insured populations. For a Maine patient facing a $200 copay, that translates to roughly $80 per fill with the card active.

Compounded Tirzepatide in Maine: Legality and Pricing

Compounded tirzepatide is legal in Maine when dispensed by a state-licensed 503A compounding pharmacy operating under a valid patient-specific prescription. Section 503A of the Federal Food, Drug, and Cosmetic Act permits compounding pharmacies to prepare medications, including tirzepatide, when an individual prescription exists and the drug is not essentially a copy of a commercially available product for which supply is adequate.

The FDA's position on tirzepatide compounding has shifted over time. During the 2022 to 2024 shortage period, tirzepatide appeared on the FDA Drug Shortage Database, which broadly permitted compounding. As of 2026, patients and prescribers should verify the current shortage status before assuming compounding is unambiguously permitted. Maine's Board of Pharmacy follows federal guidance on this point.

Pricing for compounded tirzepatide in Maine averages approximately $249 per month through licensed 503A pharmacies. That represents a 76% reduction compared to the $1,023 brand-name list price. The compounded product is typically supplied as a multi-dose vial requiring the patient to draw up each weekly injection with an insulin syringe, rather than the pre-filled pen format of brand Mounjaro.

Quality considerations matter. The FDA has issued warnings about certain compounded semaglutide and tirzepatide products containing salt forms (e.g., tirzepatide sodium) not equivalent to the branded molecule. Maine patients should confirm that the compounding pharmacy uses tirzepatide base (not a salt form), is licensed by the Maine Board of Pharmacy, and holds current accreditation from PCAB or a comparable body.

Telehealth Access to Mounjaro in Maine

Maine permits telehealth prescribing of Mounjaro with no in-person visit requirement for the initial prescription. The Maine legislature codified telehealth parity in LD 1, which requires insurers to cover telehealth services on the same terms as in-person visits. This means a video or audio consultation with a licensed prescriber is sufficient to initiate tirzepatide therapy.

Several national telehealth platforms operate in Maine and prescribe tirzepatide for both type 2 diabetes and weight management. Pricing models vary. Some platforms charge a monthly membership fee ($50 to $150) plus the medication cost. Others bundle the consultation and compounded medication into a single price ranging from $300 to $500 per month.

For patients using telehealth to obtain brand Mounjaro with commercial insurance, the key is ensuring the telehealth provider can submit the prior authorization through the patient's PBM. Not all telehealth platforms handle PA submissions. Confirming this before the first visit avoids a common frustration: receiving a prescription that the pharmacy cannot fill without additional paperwork.

Dr. Robert Gabbay, Chief Scientific and Medical Officer of the American Diabetes Association, has noted: "Telehealth has become a critical access point for diabetes medications, particularly in rural states where endocrinology availability is limited" (ADA Standards of Care 2024).

How to Reduce Your Mounjaro Cost in Maine

The cheapest path depends on your insurance status. Here is a decision framework.

Commercially insured with Mounjaro on formulary: Use the Eli Lilly savings card to bring copays to $25 per fill. Annual cost: approximately $300.

Commercially insured but Mounjaro excluded: Ask your prescriber to submit a formulary exception request citing SURPASS-2 superiority data and the ADA's recommendation of tirzepatide as a second-line agent. If denied, compounded tirzepatide at $249 per month is the next lowest-cost option.

Maine Medicaid (MaineCare): Ensure PA is submitted for type 2 diabetes. Copay is $0 to $3 per fill once approved.

Uninsured: Compounded tirzepatide at approximately $249 per month is the lowest-cost option. Some 503A pharmacies offer multi-month pricing discounts. Eli Lilly's patient assistance program may also provide brand Mounjaro at no cost for patients meeting income thresholds (generally below 400% of the federal poverty level).

Medicare Part D: Coverage varies by plan. Most Part D plans that include Mounjaro require PA for type 2 diabetes. The savings card is not usable. Patients in the coverage gap (formerly the "donut hole") pay 25% coinsurance after the Inflation Reduction Act's $2,000 annual out-of-pocket cap takes effect.

Dr. Irl Hirsch, Professor of Medicine at the University of Washington, has observed: "The gap between list price and what patients actually pay for GLP-1 receptor agonists has never been wider, and most of that gap is navigable with the right paperwork" (Diabetes Care, ADA 2024).

Mounjaro Dosing and What It Means for Cost

Tirzepatide dosing starts at 2.5 mg weekly for four weeks, then increases to 5 mg weekly. The prescriber may titrate upward in 2.5 mg increments every four weeks to a maximum of 15 mg weekly, depending on glycemic response and tolerability. The Mounjaro prescribing information specifies this titration schedule.

The cost implication is simple: brand Mounjaro costs $1,023 per month regardless of dose. A patient on 2.5 mg pays the same as a patient on 15 mg. This uniform pricing means there is no financial incentive to stay at a lower dose from a pharmacy-cost perspective, though clinical outcomes should always drive dosing decisions.

For compounded tirzepatide, pricing may differ by dose. Some 503A pharmacies charge more for higher concentrations because the active ingredient cost scales with milligrams compounded. A 2.5 mg weekly dose might cost $199 per month while a 15 mg dose could reach $349 per month at the same pharmacy. Always confirm dose-specific pricing before starting titration through a compounding pathway.

In SURPASS-2 (N=1,879), the 5 mg, 10 mg, and 15 mg doses of tirzepatide all outperformed semaglutide 1 mg for A1C reduction, with the 15 mg dose achieving a 2.37% mean reduction versus 1.86% for semaglutide. Weight loss was also dose-dependent: 12.4 kg at 15 mg versus 6.2 kg for semaglutide 1 mg at 40 weeks. These dose-response data inform conversations between patients and prescribers about the tradeoff between clinical benefit and, in the compounded pathway, incrementally higher cost.

Side Effects That Affect Adherence and Long-Term Cost

The most common side effects of tirzepatide are gastrointestinal: nausea (reported in 12% to 18% of patients across SURPASS trials), diarrhea (12% to 17%), and decreased appetite. These side effects are dose-dependent and typically attenuate after 4 to 8 weeks at a stable dose. The FDA-approved labeling includes a boxed warning regarding thyroid C-cell tumors observed in rodents, though human relevance remains unestablished.

From a cost perspective, GI side effects drive early discontinuation, which wastes the investment in the initial titration phase. A patient who fills three months of Mounjaro ($3,069 at list price) and then stops due to nausea has spent that money with limited long-term benefit. Slow titration and concurrent dietary modification (smaller, lower-fat meals) are the standard approaches to improve tolerability. The ADA recommends maintaining each dose for a minimum of four weeks before escalating, specifically to allow GI adaptation (ADA Standards of Care, Section 9).

Pancreatitis is a rare but serious risk. Patients with a history of pancreatitis should discuss this with their prescriber before starting tirzepatide. The incidence in clinical trials was <0.2% across all dose groups.